CN102139019A - Application of camellia oleifera peel extract - Google Patents
Application of camellia oleifera peel extract Download PDFInfo
- Publication number
- CN102139019A CN102139019A CN2011100743354A CN201110074335A CN102139019A CN 102139019 A CN102139019 A CN 102139019A CN 2011100743354 A CN2011100743354 A CN 2011100743354A CN 201110074335 A CN201110074335 A CN 201110074335A CN 102139019 A CN102139019 A CN 102139019A
- Authority
- CN
- China
- Prior art keywords
- camellia oleifera
- extract
- oleifera abel
- shell
- fruit shell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000526900 Camellia oleifera Species 0.000 title claims abstract description 72
- 239000000284 extract Substances 0.000 title claims abstract description 65
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 19
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 18
- 201000004384 Alopecia Diseases 0.000 claims abstract description 6
- 206010068168 androgenetic alopecia Diseases 0.000 claims abstract description 6
- 201000002996 androgenic alopecia Diseases 0.000 claims abstract description 4
- 201000007094 prostatitis Diseases 0.000 claims abstract description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 201000001514 prostate carcinoma Diseases 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 5
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 1
- 241000882890 Renova Species 0.000 claims 1
- 229960005280 isotretinoin Drugs 0.000 claims 1
- 229940059527 renova Drugs 0.000 claims 1
- 229940002683 retin-a Drugs 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 abstract 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 1
- 208000020154 Acnes Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 31
- 241000700159 Rattus Species 0.000 description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 29
- 210000002307 prostate Anatomy 0.000 description 25
- 241001122767 Theaceae Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 206010020880 Hypertrophy Diseases 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229960001712 testosterone propionate Drugs 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 229960004039 finasteride Drugs 0.000 description 6
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 235000018597 common camellia Nutrition 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 240000001548 Camellia japonica Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 3
- 102100034866 Kallikrein-6 Human genes 0.000 description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- -1 pentosan Polymers 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses application of a camellia oleifera peel extract. The camellia oleifera peel extract serving as a 5-alpha-reductase inhibitor can be used for preparing medicaments for treating prostatitis, benign prostatic hyperplasia and prostate cancers medicaments or daily health products for treating acnes or medicaments or daily health products for treating androgenetic alopecia.
Description
Technical field
The present invention relates to the new purposes of extract from fruit shell of camellia oleifera abel, be specifically related to extract from fruit shell of camellia oleifera abel and be used to prepare medicine, health product and cosmetics of everyday use, the application of treatment 5 relevant disease.
Background technology
(5 α-reductase 5AR) are the enzyme that relies on NADPH to 5, can generate active stronger dihydrotestosterone (DHT) by catalysis testosterone (T) in vivo.The activity that suppresses this enzyme can reduce the generation of DHT, and then the influence disease relevant with DHT, as prostatic hyperplasia, carcinoma of prostate, acne, male pattern baldness etc.5 has three kinds of isozymes, 5 I and 5 II and 5 III.Wherein I type enzyme is mainly expressed in the tissue of non-genitality, as liver and non-genital skin; II type enzyme is mainly expressed in the tissue of genitality, as prostate, genital skin, epididymis, seminal vesicle, testis etc.; Feature that III type enzyme is concrete and function also need further to determine.
Studies show that 5 expression and prostatic hyperplasia, carcinoma of prostate, acne and other diseases in vivo is closely related, and the 5 inhibitor can be treated above-mentioned disease well.In outgrowth prostate, the expression of I type 5 and II type 5 mRNA is obviously than high in the normal prostate tissue, and the expression of II type 5 accounts for leading.In prostate cancer tissue, no matter be the mRNA level, or protein level, the expression of I type 5 strengthens, and the expression of II type 5 weakens or does not change.In addition, I type and the expression of II type 5 in high-grade prostate cancer tissue all are higher than low-grade prostate cancer tissue.And III type enzyme is low expression in the benign prostate tissue, is high expressed in prostate cancer tissue.As seen the generation of the expression of 5 and prostatic hyperplasia and carcinoma of prostate and worsen closely relatedly, the activity that suppresses this enzyme can obviously be improved the symptom of prostatic hyperplasia, alleviates the symptom of carcinoma of prostate and reduces ill probability.Experiment showed, that repeatedly the inhibitor of 5 such as dutasteride and finasteride all can reduce prostatic volume significantly, reduce the scoring of hyperplasia of prostate, increase maximum urine flow, reduce the patient and suffer from acute urinary retention and carry out operating risk.And above-mentioned two kinds of inhibitor can significantly reduce the patient and suffer from risk of prostate cancer, reduce and suppress the growth of cancerous tissue.In addition, 5 is the extensive steroid hormone metabolism that distributes and participate in skin in skin, and its activity expression can cause diseases such as male pattern baldness, female hirsutism and acne unusually, uses the 5 inhibitor clinically and also obtains better curative effect.
Oil tea (Camellia oleifera Abel) belongs to Theaceae (Theacae), Camellia (Camellia Linn) perennial woody oilseed plant, is evergreen shrubs or dungarunga, and high 3～4m can reach 8m sometimes.It is various in style, mainly comprises common oil tea, Zhejiang Flos Carthami oil tea, Guangning Flos Carthami oil tea, lobule oil tea and south China oil tea etc.China's oil tea aboundresources and widely distributed.Whole nation camellia oleifera lam has 4,000,000hm approximately
2, mainly be distributed in southwest and each province, the southeast.Oil tea really is the fruit of oil tea, is oval, and there is the long wool hair on the surface, is made of shell of Camellia oleifera Abel (also claiming oil-tea camellia husks, oil tea peel and tea bag) and Semen Camelliae (also claiming Semen Camelliae).Wherein the content of shell of Camellia oleifera Abel accounts for about 60% of oil tea fruit.Contain abundant lignin, pentosan, tannin and tea saponin etc. in the shell of Camellia oleifera Abel,, act as a fuel usually and use or go out of use as the by-product of oil tea processing.There is report to point out shell of Camellia oleifera Abel to be used to produce industrial chemicals and culturing edible fungus such as furfural, xylitol, active carbon, potassium carbonate and potassium pyrophosphate, but the research of its biological activity and medical value is still very lacked.So deepen to the development and utilization of shell of Camellia oleifera Abel to revitalize camellia oleiferaindustry, increase oil tea added value, realize the comprehensive utilization of oil tea by-product having far reaching significance.
The preparation of extract from fruit shell of camellia oleifera abel has belonged to known technology, for example can be prepared corresponding water extract or ethanol extract according to disclosed method in patent " a kind of extract from fruit shell of camellia oleifera abel and its production and use ".
Summary of the invention
The technical problem to be solved in the present invention provides a kind of new purposes of extract from fruit shell of camellia oleifera abel, as the 5 inhibitor, can be used for the treatment of a series of diseases that cause because of 5.
In order to solve the problems of the technologies described above, the invention provides a kind of purposes of extract from fruit shell of camellia oleifera abel, as the 5 inhibitor.
Improvement as the purposes of extract from fruit shell of camellia oleifera abel of the present invention: be used for the prostatitic medicine of preparation treatment, be used to prepare the medicine for the treatment of prostatic hyperplasia, be used to prepare the medicine for the treatment of carcinoma of prostate, be used to prepare the medicine or the daily chemical products for the treatment of acne, be used to prepare the medicine or the daily chemical products for the treatment of androgenetic alopecia.
Further improvement as the purposes of extract from fruit shell of camellia oleifera abel of the present invention: extract from fruit shell of camellia oleifera abel is the separation and purification product of shell of Camellia oleifera Abel water extract, shell of Camellia oleifera Abel alcohol extract, shell of Camellia oleifera Abel water extract or the separation and purification product of shell of Camellia oleifera Abel alcohol extract.
The present inventor finds that in research process extract from fruit shell of camellia oleifera abel has the ability that suppresses 5, and can alleviate rat prostate hypertrophy symptom, suppress the growth of prostate gland cancer cell, functions such as treatment seat skin ulcer, foregoing never was in the news before the present invention.
Extract from fruit shell of camellia oleifera abel of the present invention (comprising its separation and purification product) can be applied to prevent and treat the fields such as health food, medicine and cosmetics of everyday use with the 5 relevant disease.
The invention provides a kind of wide material sources, safe and effective, economic and practical plant extract---extract from fruit shell of camellia oleifera abel, systematic research has been carried out in its effect at control 5 relevant disease, shown to have significant inhibition 5 activity, anti-prostatic hyperplasia, anti-carcinoma of prostate, suppress the effect of acne.Previous a large amount of research has shown that extract from fruit shell of camellia oleifera abel has physiology and pharmacologically actives such as significant free radical resisting, antioxidation, radioprotective, protection cardiovascular and cerebrovascular vessel, so it has safe, nontoxic, stable performance, long-term edible advantage such as have no side effect.Comprehensive above-mentioned research, can with its separately or with composite health food, medicine or the cosmetics of everyday use made of other adjuvant, be used for the control of 5 relevant disease.
Major advantage of the present invention is:
1, determined that extract from fruit shell of camellia oleifera abel suppresses the activity of 5, determined the effect of extract from fruit shell of camellia oleifera abel on control and 5 relevant disease, as prostatitis, prostatic hyperplasia, carcinoma of prostate, seat skin ulcer etc., expanded its application in health product, medicine and cosmetics of everyday use.
2, utilize the shell of Camellia oleifera Abel that goes out of use, helped reducing the wasting of resources and environmental pollution, helped increasing income of peasant.
Extract from fruit shell of camellia oleifera abel of the present invention is as the 5 inhibitor, and actual using method is oral or external application, and concrete using dosage is as follows:
When being used for the treatment of prostatitis, every day, oral consumption was 5～50mg/kg (body weight).
When being used for the treatment of prostatic hyperplasia, every day, oral consumption was 5～50mg/kg (body weight).
When being used for the treatment of carcinoma of prostate, every day, oral consumption was 5～50mg/kg (body weight).
When being used for the treatment of acne, the weight content in cosmetics of everyday use is 100,000/to 5/10000ths.
When being used for the treatment of the androgenetic alopecia medicine, the weight content in cosmetics of everyday use is 100,000/to 5/10000ths.
Description of drawings
Below in conjunction with accompanying drawing the specific embodiment of the present invention is described in further detail.
Fig. 1 is the pathology slice map (* 40) that Testosterone Propionate causes each group of rat prostate hypertrophy;
Annotate: amplifying 40 times of prostata tissue slice map: A is normal group, and B is a model group, and C is the shell of Camellia oleifera Abel low dose group, and D is the shell of Camellia oleifera Abel high dose group, and E is the finasteride group;
Fig. 2 is the inhibitory action figure of variable concentrations shell of Camellia oleifera Abel 50% ethanol extraction and three relative PC-3 cell growths of classification;
Fig. 3 is the inhibitory action figure that n-butyl alcohol phase and macroporous resin eluate thereof are grown to the PC-3 cell;
Fig. 4 be 60AL respectively 24,48,72h is to PC-3 cell inhibiting action diagram;
Fig. 5 be 80AL respectively 24,48,72h is to PC-3 cell inhibiting action diagram.
The specific embodiment
The present invention is further elaborated below by example.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.Unless otherwise defined, the same meaning that employed all specialties and scientific words and one skilled in the art are familiar with in the literary composition.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The usefulness that preferable implementation method described in the literary composition and material only present a demonstration.
1, extract from fruit shell of camellia oleifera abel is to the inhibitory action of 5
1.15 the preparation of 5 alpha-reductases
Get 3 of cleaning level female sd inbred rats, fasting can't help taking off after water spends the night cervical vertebra execution, takes out on the liver ice platform to shred.1: 5 (liver quality g: homogenate buffer volume mL) of buffer with pre-cooling, under 4 ℃, 10,000g homogenate 15min gets endochylema and partly does 100, the centrifugal 1h of 000g, precipitation is thick microgranule extract, add buffer (volume be last time the buffer addition 1/10), homogenate is as zyme extract.The Coomassie brilliant blue method is measured the amount of Protein content as 5.Packing ,-80 ℃ of refrigerators are preserved.
Carry enzyme buffer liquid: 0.32M sucrose, 0.1mM DTT, 1mM EDTA, the 20mM sodium phosphate, all the other are deionized water, pH6.5.
1.25 'alpha ' reductase activity assay method
In every 2mL buffer solution, contain testosterone T 20 μ M, NADPH 40 μ M, zyme extract 216mg, DTT 1mM, sodium phosphate 40mM, all the other are among deionized water, the pH 6.5, under 37 ℃ temperature, reaction 4min.Is the activity of enzyme with NADPH at 340nm place light absorption value fall off rate.
1.3 the preparation of extract from fruit shell of camellia oleifera abel
The selected back of oil-tea camellia husks hot air drying was pulverized 60 mesh sieve, added 50% alcoholic solution in 1: 10 by volume, and 40 ℃～60 ℃ ultrasonic 30min filter, and filtrate is evaporated to dry powder for 50 ℃, is prepared into the shell of Camellia oleifera Abel alcohol extract.
Take by weighing the extract from fruit shell of camellia oleifera abel of a certain amount of 10.0g, be mixed with suspension with 1000mL water, (with petroleum ether extraction 3 times, reuse ethyl acetate extraction 3 times is used n-butanol extraction 3 times at last earlier to use petroleum ether, ethyl acetate and n-butyl alcohol with water yield equal volume respectively to extract 3 times successively; The volume of consumption=water that every kind of extract is each).Variant polar extract merges the back and is concentrated into dry powder with Rotary Evaporators, promptly get petroleum ether phase, ethyl acetate phase, and n-butyl alcohol phase and remaining moisture level are mutually.
Take by weighing the n-butyl alcohol phase of a certain amount of 5.0g, water 5mL is mixed with suspension, cross the D101 macroporous adsorbent resin, use water, 20% (volumetric concentration) ethanol, 40% ethanol, 60% ethanol, 80% ethanol, 100% ethanol gradient elution of 2 times of column volumes respectively, each eluting is concentrated into dry powder with Rotary Evaporators.
1.4 experimental result
Get extract from fruit shell of camellia oleifera abel and separation and purification product thereof, (with the buffer solution described in 1.2 as solvent) measured its inhibition activity to 5 when concentration was 10 μ g/mL, the results are shown in Table 1.As seen after the classified extraction of 50% alcohol extract, n-butyl alcohol activity mutually is the highest, and residual activity only has 20.71%.N-butyl alcohol is crossed the macroporous resin ethanol elution mutually, and 40% ethanol elution thing activity is the highest, and residual activity only has 3.18%.Experimental technique is according to 1.2.
Table 1 extract from fruit shell of camellia oleifera abel and separation and purification part thereof are to the inhibition activity of 5
Annotate: " 20AL " represents 20% ethanol elution and gets, and all the other roughly the same.
2, extract from fruit shell of camellia oleifera abel causes the outgrowth effect of rat prostate to Testosterone Propionate
2.1 experimental technique
Get 50 of male SD rats, every body weight 220～250g takes out 10 at random and is blank group.In addition after 40 usefulness 2% pentobarbital sodiums anesthesia, routine disinfection skin is extractd bilateral testes through scrotum, the ligation of stump place, guaranteeing hemostasis, skin suture, intramuscular injection penicillin 200,000 U/ only, for three days on end.After 1 week, will go the testis rat to be divided into 4 groups at random, 10 every group, be respectively model group, finasteride positive controls, extract from fruit shell of camellia oleifera abel high dose group, extract from fruit shell of camellia oleifera abel low dose group, sub-cage rearing.Except that the blank group, all the other rat subcutaneous injection every day testosterone propionate 5mgkg
-1(0.1ml/100g body weight).And distinguish gastric infusion simultaneously, and model group is irritated stomach with normal saline 0.4ml/100g body weight, and the sample high dose group gives water extract 500mgkg
-1D
-1(0.4ml/100g body weight), sample dose group give water extract 200mgkg
-1D
-1(0.4ml/100g body weight), finasteride group are irritated stomach finasteride 1mgkg
-1D
-1(0.4ml/100g body weight), continuous use 30 days.
2.2 detection index
22d during administration collects rat 24h metabolism urine amount with metabolic cage.
Behind last administration 24h, take by weighing and respectively organize rat weight, anatomical isolation goes out rat prostate weighs with analytical balance, calculates prostate index (prostate weight in wet base mg/ body weight g).
Prostata tissue is used 10% formaldehyde fixed immediately, gets siphonal lobe, HE dyeing, cytology's form that om observation is observed each prostata tissue down.
Shred on the rats'liver dirty ice platform.With the buffer of pre-cooling 1: 5 (liver quality g: homogenate buffer volume mL), under 4 ℃, 10,000g homogenate 15min gets supernatant as the thick enzyme of 5.Containing testosterone T 20 μ M, NADPH40 μ M, DTT 1mM, sodium phosphate 40mM in the buffer solution of pH 6.5, adds this zyme extract 40 μ L, under 37 ℃ temperature, reaction 4min, assaying reaction speed is as the vigor of rat liver 5.
2.3 experimental result
The result shows from the prostate index, rat benign prostatic hyperplasia model modeling success, P＜0.01.Positive control, sample low dosage, high dose all can reduce the prostatic weight of hypertrophy, but do not reach significant difference.Specifically as shown in table 2.
Table 2 extract from fruit shell of camellia oleifera abel is to the exponential influence of rat prostate
Annotate: c represents to compare P＜0.01 with blank group
At the 22nd day of experiment, collect the voided volume of measuring in the rat 24h, the results are shown in Table 3.The urine amount of model group rat significantly is lower than blank group, and this moment, the model group rat produced prostatic hyperplasia, the symptom that voided volume reduces occurred.Positive controls and sample high dose group can significantly be improved injection Testosterone Propionate rat urine situation, and these two groups of rat urine amounts are approaching with blank group rat urine amount.Low dose group rat urine amount is compared with model group and is not reached significant difference.
Table 3 extract from fruit shell of camellia oleifera abel is to the influence of prostatic hyperplasia rat 24h urine amount
Annotate: a represents to compare P＜0.05 with blank group; B represents to compare P＜0.05 with model group
The prostata tissue pathological section, visible body of gland lumen of gland normal size under the normal group light microscopic, inner cavity surface is smooth, mamillary is seldom arranged to the intracavity projection, and the epithelial cell marshalling is cube, and a matter is few.It is outstanding in lumen of gland that the model group epithelium is papillary hyperplasia, and indentation, epithelial cell are high column, multiple layer or false multiple layer.Shell of Camellia oleifera Abel low dosage, high dose, finasteride group all can obviously be improved the symptom of model group, the body of gland marshalling, and epithelial cell not hypertrophy or hypertrophy is not obvious, and a small amount of papillae is arranged, and cell is low column or flat, marshalling, as shown in Figure 1.
The activity of 5 also significantly increases in the obvious hypertrophy of model group prostate, its liver, is increased to 0.408 ± 0.022 μ M/min, P＜0.01 from 0.251 ± 0.055 μ M/min.Positive controls and high dose group all can significantly reduce the activity of 5 in the injection Testosterone Propionate rat liver, reach extremely significant difference, see Table 4.5 activity in the low dose group rat liver is compared with model group does not have significant difference.As seen, extract from fruit shell of camellia oleifera abel also can reduce the activity by 5 in the inductive prostatic hyperplasia rat of the Testosterone Propionate body not only in the external activity that can suppress 5 effectively.In view of the substantial connection of 5 and prostatoplasia diseases, and the effect of report 5 inhibitor for treating prostatic hyperplasia, therefore think that the shell of Camellia oleifera Abel ethanol extract can be used for treating the rat prostate hypertrophy.
Table 4 extract from fruit shell of camellia oleifera abel is to the active influence of prostatic hyperplasia rat liver 5
Annotate: a represents to compare P＜0.05 with blank group; C represents to compare P＜0.01 with blank group; D represents to compare P＜0.01 with model group.
3, extract from fruit shell of camellia oleifera abel is to the effect of hypercholesterolemia model mice prostatic hyperplasia
3.1 experimental technique
Get 50 of ICR male mices, except that normal group, feed with high lipid food for all the other four groups, make that the mice weight ratio normal control group of high lipid food group is high at 20% o'clock, the modeling success, modeling was 6 weeks in the experiment.The high lipid food prescription is: 10% Adeps Sus domestica, 10% yolk powder, 1% cholesterol, 79% normal feedstuff.In the beginning of the 7th week, normal group and hyperlipidemia model group are irritated stomach with distilled water, and low dosage, middle dosage, high dose group are irritated stomach with shell of Camellia oleifera Abel 50% ethanol extract of 100mg/kg, 200mg/kg, 400mg/kg respectively.After the administration 30 days, fasting 24h weighs, and takes off cervical vertebra and puts to death mice, gets the mice prostate and weighs, and calculate the prostate index.
3.2 experimental result
As shown in Table 5, raise through high fat and hypercholesterolemia, reach the mice of obese degree, the prostate index significantly will be higher than blank group, P＜0.05.Obesity mice gives shell of Camellia oleifera Abel 50% ethanol extract when giving high lipid food, and its prostate index is to a certain degree descending.When the concentration of shell of Camellia oleifera Abel 50% ethanol extract reached 200mg/kg and 400mg/kg body weight, the prostate index was compared with model group and is all reached significance decline.As seen extract from fruit shell of camellia oleifera abel can effectively alleviate the prostatic hyperplasia that high fat hypercholesterolemia diet causes.
Table 5 extract from fruit shell of camellia oleifera abel is raised the exponential influence of mice prostate to hypercholesterolemia
Annotate: a represents to compare P＜0.05 with blank group; B represents to compare P＜0.05 with model group; D represents to compare P＜0.01 with model group.
4, extract from fruit shell of camellia oleifera abel is to the inhibitory action of prostate gland cancer cell PC-3
4.1 experimental technique
The trophophase PC-3 cell of taking the logarithm, after the trypsinization, regulating concentration of cell suspension is 1 * 10
5Individual/ml, every hole adds 100 μ L cell suspension in 96 orifice plates, and mixing gently on the agitator is put into 37 ℃, 5%CO
2Cultivate in the incubator.Behind the adherent 24h, every hole adds the culture fluid 100 μ L that contain extract from fruit shell of camellia oleifera abel, and 5 Concentraton gradient are set, the system final concentration of making is respectively 12.5,25,50,100,200 μ g/mL, and background group, blank group are set, answer holes for 5 every group, cultivation 24,48,72h.4h before end, every hole adds 50 μ L MTT solution, 37 ℃, 5%CO
2The middle cultivation 4h that continues.Take out 96 orifice plates, the centrifugal 5min of 1800r/min gets rid of liquid, blots residual liquid with paper, and every hole adds the acid DMSO of 150 μ L, and vibration 10min measures OD on the microplate reader
492
Inhibitory rate of cell growth (%)=[1-(OD
Sample-OD
Background)/(OD
Blank-OD
Background)] * 100%
Annotate: background group: 100 μ L culture fluid+100 μ L culture fluid;
Blank group: 100 μ L cell suspension+100 μ L culture fluid;
Sample sets: the extract from fruit shell of camellia oleifera abel solution of 100 μ L cell suspension+100 μ L variable concentrations.
4.2 experimental result
As shown in Figure 2,50% ethanol extraction and the increase of n-butyl alcohol along with concentration strengthen the effect of PC-3 cell inhibiting, and effect does not present concentration dependent to the PC-3 cell inhibiting for ethyl acetate phase and aqueous phase substance.50% ethanol extraction is after the phase-splitting extraction, and n-butyl alcohol suppresses the PC-3 cell activity mutually to be strengthened, and 503nhibiting concentration is 54.8 μ g/mL, and the 503nhibiting concentration of 50% ethanol extraction is 151.6 μ g/mL.
N-butyl alcohol is behind the macroporous resin eluting, and 20% ethanol elution thing and 40% ethanol elution thing are to PC-3 cell inhibiting ability drop, and 60% ethanol elution thing and 80% ethanol elution thing action effect significantly strengthen, as shown in Figure 3.At 48h, the 503nhibiting concentration of 60AL is 43.0 μ g/mL, and the 503nhibiting concentration of 80AL is 28.1 μ g/mL, as shown in Figure 4 and Figure 5.
Conclusion: extract from fruit shell of camellia oleifera abel or its separation and purification product can suppress the activity of 5; Reduce the heavy and prostate index of prostate that Testosterone Propionate causes the rat prostate model of hyperplasia, increase rat urine flow, suppress the activity of 5 in the rat body; Reduce the heavy and prostate index of mice prostate that hyperlipidemia model causes; The propagation that suppresses prostatic cell; Prevention and treatment seat skin ulcer.Can use it for the exploitation of health food, medicine and cosmetics of everyday use, be used to prevent and treat the disease relevant with 5.
At last, it is also to be noted that what more than enumerate only is several specific embodiments of the present invention.Obviously, the invention is not restricted to above embodiment, many distortion can also be arranged.All distortion that those of ordinary skill in the art can directly derive or associate from content disclosed by the invention all should be thought protection scope of the present invention.
Claims (7)
1. the purposes of extract from fruit shell of camellia oleifera abel is characterized in that: as the 5 inhibitor.
2. the purposes of extract from fruit shell of camellia oleifera abel according to claim 1 is characterized in that: the application in preparation treatment prostatitis medicine.
3. the purposes of extract from fruit shell of camellia oleifera abel according to claim 1 is characterized in that: the application in preparation treatment prostatic hyperplasia medicine.
4. the purposes of extract from fruit shell of camellia oleifera abel according to claim 1 is characterized in that: the application in preparation treatment carcinoma of prostate medicine.
5. the purposes of extract from fruit shell of camellia oleifera abel according to claim 1 is characterized in that: the application in preparation Retinoids, Retin-A, Renova, Accutane or daily chemical products.
6. the purposes of extract from fruit shell of camellia oleifera abel according to claim 1 is characterized in that: the application in preparation treatment androgenetic alopecia medicine or daily chemical products.
7. according to the purposes of any one extract from fruit shell of camellia oleifera abel in the claim 1 ~ 6, it is characterized in that: described extract from fruit shell of camellia oleifera abel is the separation and purification product of shell of Camellia oleifera Abel water extract, shell of Camellia oleifera Abel alcohol extract, shell of Camellia oleifera Abel water extract or the separation and purification product of shell of Camellia oleifera Abel alcohol extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110074335 CN102139019B (en) | 2011-03-26 | 2011-03-26 | Application of camellia oleifera peel extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110074335 CN102139019B (en) | 2011-03-26 | 2011-03-26 | Application of camellia oleifera peel extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102139019A true CN102139019A (en) | 2011-08-03 |
| CN102139019B CN102139019B (en) | 2013-04-10 |
Family
ID=44406961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110074335 Expired - Fee Related CN102139019B (en) | 2011-03-26 | 2011-03-26 | Application of camellia oleifera peel extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102139019B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102428833A (en) * | 2011-09-20 | 2012-05-02 | 丽水市林业科学研究院 | Method for cultivating black fungus by Camellia oleifera Po |
| CN106727025A (en) * | 2017-01-13 | 2017-05-31 | 华南理工大学 | A kind of camellia skin cream and preparation method thereof |
| CN108404074A (en) * | 2018-04-17 | 2018-08-17 | 郭哲 | A kind of Chinese medicine hair-growing liquid |
| CN109833377A (en) * | 2019-03-27 | 2019-06-04 | 长沙理工大学 | A kind of extract from fruit shell of camellia oleifera abel and its preparation method and application |
| CN113069493A (en) * | 2021-04-13 | 2021-07-06 | 江山之间生物科技有限公司 | Application of oil tea extract in inhibiting sebum secretion |
| WO2021215882A1 (en) * | 2020-04-24 | 2021-10-28 | 바이오스펙트럼 주식회사 | Composition for preventing hair loss or promoting hair growth comprising camellia pericarp extract as active ingredient |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101560265A (en) * | 2009-06-01 | 2009-10-21 | 浙江大学 | Method for preparing oil-tea camellia husk polysaccharide and purifying method |
| CN101744948A (en) * | 2008-12-19 | 2010-06-23 | 浙江大学 | Extract from fruit shell of camellia oleifera abel and preparation method and application thereof |
-
2011
- 2011-03-26 CN CN 201110074335 patent/CN102139019B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744948A (en) * | 2008-12-19 | 2010-06-23 | 浙江大学 | Extract from fruit shell of camellia oleifera abel and preparation method and application thereof |
| CN101560265A (en) * | 2009-06-01 | 2009-10-21 | 浙江大学 | Method for preparing oil-tea camellia husk polysaccharide and purifying method |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102428833A (en) * | 2011-09-20 | 2012-05-02 | 丽水市林业科学研究院 | Method for cultivating black fungus by Camellia oleifera Po |
| CN102428833B (en) * | 2011-09-20 | 2013-05-01 | 丽水市林业科学研究院 | Method for cultivating black fungus by Camellia oleifera Po |
| CN106727025A (en) * | 2017-01-13 | 2017-05-31 | 华南理工大学 | A kind of camellia skin cream and preparation method thereof |
| CN108404074A (en) * | 2018-04-17 | 2018-08-17 | 郭哲 | A kind of Chinese medicine hair-growing liquid |
| CN109833377A (en) * | 2019-03-27 | 2019-06-04 | 长沙理工大学 | A kind of extract from fruit shell of camellia oleifera abel and its preparation method and application |
| CN109833377B (en) * | 2019-03-27 | 2021-06-18 | 长沙理工大学 | Camellia oleifera Abel extract and preparation method and application thereof |
| WO2021215882A1 (en) * | 2020-04-24 | 2021-10-28 | 바이오스펙트럼 주식회사 | Composition for preventing hair loss or promoting hair growth comprising camellia pericarp extract as active ingredient |
| CN113069493A (en) * | 2021-04-13 | 2021-07-06 | 江山之间生物科技有限公司 | Application of oil tea extract in inhibiting sebum secretion |
| CN113069493B (en) * | 2021-04-13 | 2023-07-07 | 江山之间生物科技有限公司 | Application of camellia oleifera leaf extract in sebum secretion inhibition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102139019B (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139019B (en) | Application of camellia oleifera peel extract | |
| CN101433620B (en) | Longan water-soluble active substance as well as extraction method and use thereof | |
| CN101628925B (en) | Application of microwave technology in processing oil-tea camellia seeds | |
| CN102349924B (en) | Centella asiatica triterpenic acid single-glucopyranoside composition, its preparation method, its quantitative analysis method and its application | |
| CN106165848A (en) | Garlic skin dietary fiber and steam explosion thereof and enzymolysis modified technology of preparing and application | |
| Srivastava et al. | Effects of microwave, ultrasound, and various treatments on the reduction of antinutritional factors in elephant foot yam: A review | |
| CN103948023B (en) | The health food of a kind of develop immunitypty and improving water flood and two-step fermentation preparation method thereof | |
| CN101879156B (en) | Medicinal composition and application thereof | |
| WO2019174369A1 (en) | Method for using tea seed meal as additive for aquatic animals and ruminants | |
| CN107535651B (en) | Russian black tea and preparation method thereof | |
| CN103243015A (en) | Table vinegar with antioxidant health care function and preparation method thereof | |
| CN104254594A (en) | Functional makgeolli with improved radioactive strontium discharge and antioxidant activity, containing selenium solution, and preparation method thereof | |
| CN105766377B (en) | A kind of cultural method improving black fungus flavones content and type | |
| Ajibade et al. | Antifungal efficacy of saponin extracted from Phyllanthus niruri | |
| CN103932179B (en) | A kind of health food and two-step fermentation preparation method thereof releasing the pressure and protect liver | |
| CN105998222A (en) | Probiotic fermented unprocessed common monkshood daughter root composition and preparation method and application thereof | |
| CN108392508A (en) | Application of the white lotus parthenium extract in preparing anti-inflammatory drug | |
| CN109675001A (en) | The Chinese medicine composition for preventing and treating cage culture fresh water fish disease | |
| Jin et al. | Enhanced extraction genistein from pigeon pea [Cajanus cajan (L.) Millsp.] roots with the biotransformation of immobilized edible Aspergillus oryzae and Monacus anka and antioxidant activity evaluation | |
| CN102665760B (en) | Primary bile acid and secondary bile acid generation regulator | |
| CN109364110A (en) | A method of flavones is extracted from U.S. rattan shell | |
| CN105395927B (en) | Highland barley bran extract is preparing the application in alpha-glucosidase activity inhibitor | |
| CN105748610A (en) | Solid fermentation method for polygonum hydropiper linn preparations by aid of bacillus subtilis, fermentation products of solid fermentation method and application | |
| CN101829174A (en) | Application of erigeron breviscapus extract in preparing anti-tumor or angiogenesis-suppressing medicaments, health-care food or cosmetics | |
| CN105454956A (en) | A hericium erinaceus-common cattail solid fermentation functional drink and a preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |